Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TG Therapeutics (TGTX)

TG Therapeutics Reports Preliminary 2023 BRIUMVI Revenue of $89 Million

Neutral Impact 3 of 5 earnings Written later

TG Therapeutics preliminarily reported unaudited U.S. BRIUMVI net product revenue of approximately $40 million for the fourth quarter of 2023 and $89 million for the full year, with a year-end 2023 cash position of approximately $215 million. It also set 2024 targets of $220 million to $260 million in full-year BRIUMVI revenue and about $250 million in operating expense, and disclosed a January 7, 2024 license for azer-cel from Precision BioSciences. The filing does not give prior-period comparisons, so the figures alone do not show whether results improved.

Key points

  • Preliminary U.S. BRIUMVI net product revenue of approximately $40 million for Q4 2023 and $89 million for full year 2023, unaudited
  • 2024 targets: $41 million to $46 million for Q1 BRIUMVI revenue and $220 million to $260 million for full year; full-year operating expense of approximately $250 million
  • Azer-cel license with Precision BioSciences dated January 7, 2024: $7.5 million upfront and up to $288 million in additional milestone payments, plus royalties

The filing

CompanyTG Therapeutics (TGTX)
Form8-K, current report
Filed with the SECJan 10, 2024, 7:37 AM ET
Accession number0001437749-24-001061

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 10, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.